Please assess the completion status of the following clinical trial:

Trial Title: Oleogel-S10 in Wound Healing of Inherited Epidermolysis Bullosa (BEB-10)

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Patients aged 1-95 years~2. Patient and/or his/her legal representative was informed, read and understood the patient information/informed consent form and gave written informed consent~3. Patients with inherited EB with at least 1 skin lesion between 10 cm2 and 200 cm2 (alternatively 2 comparable lesions of at least 5 cm2 each)~4. Patient and/or his/her legal representative was able and willing to follow study procedures and instructions including the following:~   1. Application of Oleogel-S10 on (1 half of) the wound at every wound dressing change~  2. Regular visits during the treatment period (14 days in 'recent wounds' to 28 days in 'chronic wounds')~5. Negative pregnancy test in women of childbearing potential within 7 days before start of treatment~6. Women of childbearing potential agreed to use an effective method of contraception (Pearl Index \< 1, e.g. hormonal contraception including the combined oral contraceptive pill, the transdermal patch, and the contraceptive vaginal ring, intrauterine devices or sterilization) during treatment and for at least 6 months thereafter~7. Men of procreative capacity agreed to use an effective method of contraception during treatment and for at least 6 months thereafter~Exclusion Criteria:~1. Systemic treatment with steroids during the last 30 days~2. Uncontrolled diabetes mellitus or diabetic ulcers~3. Diseases or conditions that could, in the opinion of the investigator, interfere with the assessment of safety, tolerance or efficacy~4. Skin disorders adversely affecting wound healing or involving the areas eligible for study treatment~5. Hypersensitivity to the trial medication or surgical dressings to be used~6. Multiple allergic disorders~7. Administration of investigational drugs within 3 months before screening~8. Investigations or changes in management for an existing medical condition~9. Low probability to complete the study per protocol for whatever reason

- Gender: ALL
- Minimum Age: 1 Year
- Maximum Age: 95 Years
- Healthy Volunteers: f

Study Arms:
- Oleogel-S10 (Type: EXPERIMENTAL): The eligible wound (half) was topically treated with Oleogel-S10 and covered with a non-adhesive wound dressing (Mepilex®) on Day 0. Wound dressings were changed about every 24 to 48 hours until discharge from hospital or until the end of treatment at Day 14 in 'recent wounds' or Day 28 in 'chronic wounds'.
- Non-adhesive wound dressing (Type: OTHER): Mepilex® soft silicone faced polyurethane foam dressing was used as non-active comparator. The eligible wound (half) was covered with Mepilex® as control on Day 0. Wound dressings were changed about every 24 to 48 hours until discharge from hospital or until the end of treatment at Day 14 in 'recent wounds' or Day 28 in 'chronic wounds'.

Based on this trial design, predict the completion outcome and termination type (if applicable).